<DOC>
	<DOC>NCT00068133</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of VLTS-589 compared with placebo, administered bilaterally to the lower extremities, in subjects with intermittent claudication and to determine the effect of VLTS-589 in peak walking time (PWT) for subjects receiving VLTS-589 compared with subjects receiving placebo.</brief_summary>
	<brief_title>Trial of VLTS-589 in Subjects With Intermittent Claudication</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Inclusion criteria: Men or women between 40 and 80 years of age, Must give informed consent, Current medical history of peripheral arterial disease, which includes the following symptoms: leg pain, leg discomfort or leg weakness Exclusion criteria: Ulcers or gangrene, History of cancer (except skin cancer) within the past 5 years, Participation in another clinical trial within 30 days of enrollment in this trial, Unwillingness or inability to comply with all study requirements</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2005</verification_date>
</DOC>